Catch-all.

A prospective study of nearly 3000 patients with solid tumors treated at Mayo over the last couple of years reported 6.4% had clinically actionable mutations detected with a universal testing approach that would not have been detected by phenotype or family history–based testing criteria. | Samadder, JAMA Oncol 2020